Pieris Pharmaceuticals, Inc. (PIRS) SEC Filing 8-K Material Event for the period ending Wednesday, October 2, 2019

Pieris Pharmaceuticals, Inc.

CIK: 1583648 Ticker: PIRS

View differences made from one to another to evaluate Pieris Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pieris Pharmaceuticals, Inc..


Assess how Pieris Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pieris Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Pieris Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: PIRS
CIK: 1583648
Form Type: 8-K Corporate News
Accession Number: 0001583648-19-000066
Submitted to the SEC: Wed Oct 02 2019 7:58:59 AM EST
Accepted by the SEC: Wed Oct 02 2019
Period: Wednesday, October 2, 2019
Industry: Commercial Physical And Biological Research
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: